Source comparison
Tesamorelin + Ipamorelin Blend Side Effects: Clinical vs Anecdotal Comparison
Injection site erythema/swelling 15–30% (Grade 1 only) Within 6–24 hours post-injection 24–72 hours in 85% of cases Mechanical tissue stretch + histamine release from rapid injection Technique-dependent. Slowest injection speed eliminates most cases Transient
This comparison does not assign a generated winner or score.
- Injection site erythema/swelling
- 15–30% (Grade 1 only)
- Within 6–24 hours post-injection
- 24–72 hours in 85% of cases
- Mechanical tissue stretch + histamine release from rapid injection
- Technique-dependent. Slowest injection speed eliminates most cases
- Transient joint discomfort (arthralgia)
- 8–12%
- Week 2–4 of protocol
- Self-limiting within 2–3 weeks
- GH-mediated fluid shift into joint spaces, resolves as aldosterone adapts
- Does not correlate with long-term joint damage; no cases required intervention
- Subcutaneous water retention
- ~20% during first month
- Week 2–3
- Peak week 4–6, resolves by week 8–10
- Aldosterone upregulation in response to GH pulse; body recalibrates over 6–8 weeks
- Temporary cosmetic effect; no cardiovascular or renal burden in any published trial
- Morning fasting glucose elevation
- 3–5%
- Variable, typically week 4+
- Persists while on protocol, reverses upon cessation
- GH antagonises insulin signalling in hepatic tissue (expected mechanism, not pathology)
- Clinically insignificant in non-diabetic subjects; monitored in metabolic studies
- Headache (mild)
- 6–9%
- Variable
- Resolves spontaneously within 48 hours
- Likely histamine or transient blood pressure fluctuation; poorly characterised
- No pattern in timing or dose-response; considered unrelated to peptide mechanism
- Cortisol or prolactin elevation
- 0% in combination trials
- N/A
- Ipamorelin's ghrelin selectivity prevents ACTH/prolactin cross-activation seen with non-selective secretagogues
- Key advantage of this specific blend over standalone GHRH protocols